The text of the following statement was released by the Governments of the Republic of Armenia and the United States on ...
Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (ORPATHYS ®) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback